Becton Dickinson on Thursday raised the lower end of its adjusted profit forecast for full-year 2026 after beating Wall Street estimates for third-quarter profit and revenue, helped by demand for its drug-delivery devices and surgical equipment.
The medical device maker’s shares were up 4% higher in early trading.
The company expects fiscal 2027 revenue growth to start from a low-single-digit baseline, taking a conservative posture due to volatility in oil prices, CEO Tom Polen said on a post earnings call.
Resins and molded plastics, used to make syringes and catheters, account for about 5% of cost of goods sold and higher oil prices could add $60 million to $70 million to Becton Dickinson’s costs, though the company expects to offset the impact through price increases.
“Oil is a factor that we are monitoring very closely… I think the most important is we are acting on it. We are not waiting and seeing this impact us. We have pricing actions underway already,” said CFO Vitor Rogue.
The company now expects 2026 adjusted profit per share between $12.62 and $12.72, compared with its previous forecast of $12.52 to $12.72.
Analysts on an average expect annual profit of $12.61 per share, according to LSEG data.
“After some quarters of rockiness, it is encouraging to see a solid delivery, Citi analysts said.
The company earned adjusted profit per share of $3.23 for the quarter ended June 30, above estimates of $3.14.
It posted quarterly revenue of $4.98 billion, topping estimates of $4.89 billion.
